Pharmaceutical Ingredients Lamotrigine CAS 84057-84-1 for Antibacterial Usage

Pharmaceutical Ingredients Lamotrigine CAS 84057-84-1 for Antibacterial Usage

Product Name: Lamotrigine
Synonyms: 4-triazine-3,5-diamine,6-(2,3-dichlorophenyl)-2;3,5-DIAMINO-6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZINE;6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZINE-3,5-DIAMINE;LTG;BW-430C;LAMICTAL;LAMOTRIGIN;LAMOTRIGINE
CAS: 84057-84-1
MF: C9H7Cl2N5
MW: 256.09
EINECS: 281-901-8

Lamotrigine Usage And Synthesis

Chemical Properties White to Cream Coloured Powder
Usage An anticonvulsant. Inhibits glutamate release, possible through inhibition of Sodium, Potassium and Calcium currents. Used in treatment of bipolar depression.
Usage antibacterial
Usage For the adjunctive treatment of partial seizures in epilepsy and generalized seizures of Lennox-Gastaut syndrome. Also for the maintenance treatment of bipolar I disorder and depression.
Biological Activity Anticonvulsant. Inhibits glutamate release, possibly through inhibition of Na + , K + and Ca 2+ currents.

Lamotrigine Medical uses

Epilepsy
Lamotrigine is approved in the US for the treatment of partial seizures.[8] It is considered a first-line drug for primary generalised tonic-clonic seizures (includes simple partial, complex partial and secondarily generalised seizures), and as an adjuvant therapy in partial seizures (focal onset tonic-clonic, atypical absence, myoclonic, and due to Lennox-Gastaut syndrome). As well, it is used as an alternative drug for absence seizure and atypical absence, myoclonic, and atonic seizures.[9][10]

Lamotrigine is one of a small number of FDA-approved therapies for seizures associated with Lennox-Gastaut syndrome, a severe form of epilepsy. Typically developing before four years of age, LGS is associated with developmental delays. There is no cure, treatment is often complicated, and complete recovery is rare. Symptoms include the atonic seizure (also known as a "drop attack"), during which brief loss of muscle tone and consciousness cause abrupt falls. Lamotrigine significantly reduces the frequency of LGS seizures, and is one of two medications known to decrease the severity of drop attacks.[11] Combination with valproate is common, but this increases the risk of lamotrigine-induced rash, and necessitates reduced dosing due to the interaction of these drugs.

Bipolar disorder
Lamotrigine is approved in the US for maintenance treatment of bipolar I disorder.[13] While traditional anticonvulsant drugs are predominantly antimanics, lamotrigine is most effective for preventing the recurrent depressive episodes of bipolar disorder. The drug seems ineffective in the maintenance of current rapid-cycling, acute mania, or acute depression in bipolar disorder; however, it is effective at prevention of or delaying the mania, depressive, or rapid cycle.[14] According to studies in 2007, lamotrigine may treat bipolar depression without triggering mania, hypomania, mixed states, or rapid-cycling.

Lamotrigine Other uses

Off-label uses include the treatment of peripheral neuropathy, trigeminal neuralgia, cluster headaches, migraines, and reducing neuropathic pain.[23][24][25] Off-label psychiatric usage includes the treatment of treatment-resistant obsessive-compulsive disorder,[26] depersonalization disorder,[27] hallucinogen persisting perception disorder,[28] schizoaffective disorder,[29] borderline personality disorder,[30] and post-traumatic stress disorder.[31] Lamotrigine has been studied as an adjunctive therapy for treatment of refractory unipolar depression, attaining efficacy on the secondary metric for treatment outcomes (Clinical Global Impressions), but not the primary metrics (Montgomery–Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression).[2] In at least two cases, lamotrigine seemed efficacious for Kleine-Levin syndrome[32][33] but caused no improvement in at least one case.[34]

Lamotrigine has also been found to have a role in the treatment of adult attention deficit hyperactivity disorder with comorbid depression.[35]

It is also appropriate for the treatment of Lennox–Gastaut syndrome.